Due to the mutual offset of vasodilation and vasoconstriction, the effect of treating HF with enkephalinase inhibitor alone may be poor.[8] In the follow-up study, the combination of enkephalinase inhibitor and angiotensin receptor antagonist was used to prepare salkubatron valsartan. The gene discussed is MME; the disease is hydrops fetalis.